Evaluation of Soybean Peptides Product on Regulation of Blood Pressure Effect in Humans

Chung Shan Medical University

Status: Completed

Conditions: Hypertension

Treatments: Dietary Supplement: Soybean peptides; Dietary Supplement: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT03828955

CS15123

Details and patient eligibility

About

This is the report to assess supplementation with soybean peptides on blood pressure among people with mild hypertension. Overall, soybean peptide consumption for 8 weeks could successfully reduce mean diastolic and systolic BP through the suppression of Angiotensin-converting enzyme (ACE) linked to downstream suppression of angiotensin II formation, which further decreases the sympathetic outflow that leads to hypertension.

Full description

This is the report to assess supplementation with soybean peptides on blood pressure among people with mild hypertension. Thirty subjects with systolic blood pressure (SBP) between 120 and 159 mm Hg and/or diastolic blood pressure (DBP) between 80 and 99 mm Hg were randomized to ingest 2 bags of soybean peptides or placebo per day for 8 weeks of a stage. Anthropometric measurements (blood pressure, body weight, body fat) and blood biochemical markers including fasting blood glucose (FBG), albumin, total cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, creatinine (Cr), blood urea nitrogen (BUN), AST, ALT) were examined every four weeks.

Enrollment: 30 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Eligible subjects were untreated hypertensive men or women aged between 20 and 80 years old with SBP between 120 and 159 mmHg and/or DBP between 80 and 99 mmHg as measured in a sitting position

Exclusion criteria

• Subjects were excluded if they had a history of major cardiovascular disease or severe liver dysfunction;
• Diastolic blood pressure ≥ 100 mmHg or Systolic blood pressure ≥ 160 mmHg;
• Alcoholic;
• US-controlled diabetics;
• Stoke in past one year;
• Mental diseases or melancholia;
• Pregnancy or breast-feeding a child;
• Renal dysfunction;
• Allergic to Soybean peptides.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

30 participants in 2 patient groups, including a placebo group

Soybean peptides

Experimental group

Description:

Subjects receive two bags soybean peptides per day for 8 weeks of a stage.

Treatment:

Dietary Supplement: Soybean peptides

Placebo

Placebo Comparator group

Description:

Subjects receive two bags starch placebo of similar appearance per day for 8 weeks of a stage.

Treatment:

Dietary Supplement: Placebo